Title:
HETEROCYCLIC FUSED PYRIMIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/103897
Kind Code:
A1
Abstract:
A heterocyclic fused pyrimidine derivative, a pharmaceutical composition thereof, and an application thereof. A heterocyclic fused pyrimidine derivative (I), and an isomer, prodrug, stable isotope derivative, or pharmaceutically acceptable salts thereof have the following structure. The heterocyclic fused pyrimidine derivative can inhibit the ATR level well both in vivo and in vitro. Furthermore, the heterocyclic fused pyrimidine derivative can be also used for effectively treating diseases caused by the abnormal ATR level such as cancer.
Inventors:
ZHAO ZHIMING (CN)
YANG WEI (CN)
WU ZHIHENG (CN)
TONG ZHAOLONG (CN)
GAO DAXIN (CN)
YANG WEI (CN)
WU ZHIHENG (CN)
TONG ZHAOLONG (CN)
GAO DAXIN (CN)
Application Number:
PCT/CN2019/119899
Publication Date:
May 28, 2020
Filing Date:
November 21, 2019
Export Citation:
Assignee:
SHANGHAI DE NOVO PHARMATECH CO LTD (CN)
International Classes:
A61K31/7064; A61P35/00; C07D417/00; C07D419/14
Domestic Patent References:
| WO2010151601A1 | 2010-12-29 | |||
| WO2007127175A2 | 2007-11-08 | |||
| WO2008070740A1 | 2008-06-12 |
Foreign References:
| CN103946222A | 2014-07-23 |
Other References:
LIU, K.K.-C ET AL.: "Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors", .BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, no. 15, 6 June 2012 (2012-06-06), pages 5114 - 5117, XP028428296, DOI: 20200215181715A
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF:
Previous Patent: PYRROLO[2,3-B]PYRIDINES AS HPK1 INHIBITOR AND USES THEREOF
Next Patent: LED LIGHT BULB MANUFACTURING METHOD
Next Patent: LED LIGHT BULB MANUFACTURING METHOD